Tech Company Financing Transactions
aFraxis Funding Round
aFraxis, based in La Jolla, secured $1.2 million from private investors.
Transaction Overview
Company Name
Announced On
5/16/2010
Transaction Type
Venture Equity
Amount
$1,200,000
Round
Undisclosed
Investors
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Acquired or Merged
Industry
Biopharmaceutical
Mailing Address
11099 N Torrey Pines Rd. 290
La Jolla, CA 92037
USA
La Jolla, CA 92037
USA
Phone
Website
Email Address
Overview
Afraxis is discovering and developing drugs to treat diseases of the central nervous system, including schizophrenia, Alzheimer's disease, Fragile X syndrome and autism spectrum disorders. Recent scientific discoveries have linked these disorders to underlying defects in the development and function of specialized structures of the neural synapse, called dendritic spines.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Jay Lichter
Chief Scientific Officer
David Campbell
VP - Bus. Development
Carmine Stengone
VP - R & D
Christopher Rex
Browse more venture capital transactions:
Prev: 5/14/2010: Data Locker venture capital transaction
Next: 5/17/2010: Zend Technologies venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site come from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs